New insider Su Wei-Guo claimed ownership of 3,563,905 units of ordinary shares and claimed ownership of 237,063 units of American depositary shares (SEC Form 3)
$HCM
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 03/16/2026 |
3. Issuer Name and Ticker or Trading Symbol
HUTCHMED (China) Ltd [ HCM ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| ordinary shares | 3,563,905 | D | |
| American depositary shares(1) | 237,063 | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Share option (right to buy)(2) | 03/27/2017 | 03/26/2027 | ordinary shares | 1,000,000 | (3) | D | |
| Share option (right to buy)(2) | 03/19/2018 | 03/18/2028 | ordinary shares | 1,000,000 | (4) | D | |
| Share option (right to buy)(2) | 04/28/2020 | 04/27/2030 | American depositary shares | 157,940 | $22.09(5) | D | |
| Share option (right to buy)(2) | 12/14/2020 | 12/13/2030 | American depositary shares | 3,792 | $29(5) | D | |
| Share option (right to buy)(2) | 03/26/2021 | 03/25/2031 | American depositary shares | 56,480 | $27.94(5) | D | |
| Share option (right to buy)(2) | 12/14/2021 | 12/13/2031 | American depositary shares | 4,986 | $35.21(5) | D | |
| Share option (right to buy)(6) | 08/05/2024 | 08/04/2034 | ordinary shares | 1,405,767 | (7) | D | |
| Share option (right to buy)(6) | 06/09/2025 | 06/08/2035 | ordinary shares | 1,493,435 | (8) | D | |
| Long Term Incentive Plan awards granted on 03/13/2024 | (9) | (9) | ordinary shares | 39,862 | (9) | I | Held by Long Term Incentive Plan trustee |
| Long Term Incentive Plan awards granted on 08/05/2024 | (10) | (10) | ordinary shares | 169,977 | (10) | I | Held by Long Term Incentive Plan trustee |
| Explanation of Responses: |
| 1. Each American depositary share represents 5 ordinary shares. |
| 2. The share options granted are exercisable subject to, amongst other relevant vesting criteria, the vesting schedule of 25% on each of the first, second, third and fourth anniversaries of the date of grant of share options. |
| 3. The exercise price for the share option is GBP3.105 per ordinary share. |
| 4. The exercise price for the share option is GBP4.974 per ordinary share. |
| 5. The exercise price for the share option is denominated in United States dollar per American depositary share. |
| 6. The exercise of the share options granted is conditional upon the fulfilment of performance targets prescribed by the Board for the relevant performance periods (2023-2025, 2024-2026 and 2025-2027), as set out in the respective grant letters. For each grant, the number of share options that may become exercisable will be determined on the date of announcement of the annal results of the Company for the final financial year of the applicable performance period (i.e. the annual results announcements for the financial years ending December 31, 2025, 2026 and 2027, respectively). Vesting will occur two business days after the relevant results announcement. Any share options in respect of which the applicable performance targets are not met will lapse accordingly. |
| 7. The exercise price for the share option is HKD29.200 per ordinary share. |
| 8. The exercise price for the share option is HKD25.500 per ordinary share. |
| 9. 25% of Long Term Incentive Plan Awards vesting on each of March 13, 2025, March 13, 2026, March 13, 2027 and March 13, 2028. |
| 10. All Long Term Incentive Plan Awards will vest in 2027, three weeks after the date of completion of the share purchase for the awards for the financial year ending December 31, 2026. |
| /s/ Su Wei-guo | 03/16/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||